Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.

Liu LY, Wang F, Zhang XY, Huang P, Lu YB, Wei EQ, Zhang WP.

PLoS One. 2012;7(10):e44933. doi: 10.1371/journal.pone.0044933. Epub 2012 Oct 11.

2.

NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.

Zhang XQ, Lu JT, Jiang WX, Lu YB, Wu M, Wei EQ, Zhang WP, Tang C.

Neuroscience. 2015 Apr 16;291:230-40. doi: 10.1016/j.neuroscience.2015.02.007. Epub 2015 Feb 12.

PMID:
25684751
3.

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Tan B, Dong S, Shepard RL, Kays L, Roth KD, Geeganage S, Kuo MS, Zhao G.

J Biol Chem. 2015 Jun 19;290(25):15812-24. doi: 10.1074/jbc.M114.632141. Epub 2015 May 5.

4.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.

Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo MS, Gillig J, Parthasarathy S, Burkholder TP, Smith MC, Geeganage S, Zhao G.

J Biol Chem. 2013 Feb 1;288(5):3500-11. doi: 10.1074/jbc.M112.394510. Epub 2012 Dec 13.

5.

FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.

Schuster S, Penke M, Gorski T, Gebhardt R, Weiss TS, Kiess W, Garten A.

Biochem Biophys Res Commun. 2015 Mar 6;458(2):334-40. doi: 10.1016/j.bbrc.2015.01.111. Epub 2015 Feb 3.

PMID:
25656579
6.

Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.

Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, Wang F, Fang SH, Lu YB, Hu H, Wei EQ, Zhang WP.

Eur J Pharmacol. 2012 Jan 15;674(2-3):163-70. doi: 10.1016/j.ejphar.2011.11.017. Epub 2011 Nov 19.

PMID:
22119381
7.

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.

Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.

Cancer Lett. 2016 Aug 28;379(1):1-11. doi: 10.1016/j.canlet.2016.05.024. Epub 2016 May 24.

PMID:
27233476
8.

Up-regulation of nicotinamide phosphoribosyltransferase and increase of NAD+ levels by glucose restriction extend replicative lifespan of human fibroblast Hs68 cells.

Yang NC, Song TY, Chang YZ, Chen MY, Hu ML.

Biogerontology. 2015 Feb;16(1):31-42. doi: 10.1007/s10522-014-9528-x. Epub 2014 Aug 22.

PMID:
25146190
9.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.

Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T.

PLoS One. 2008 May 21;3(5):e2267. doi: 10.1371/journal.pone.0002267.

10.

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A, Raffaelli N, De Flora A, Nencioni A, Bruzzone S.

J Biol Chem. 2013 Sep 6;288(36):25938-49. doi: 10.1074/jbc.M113.470435. Epub 2013 Jul 23.

11.

Monocyte-derived extracellular Nampt-dependent biosynthesis of NAD(+) protects the heart against pressure overload.

Yano M, Akazawa H, Oka T, Yabumoto C, Kudo-Sakamoto Y, Kamo T, Shimizu Y, Yagi H, Naito AT, Lee JK, Suzuki J, Sakata Y, Komuro I.

Sci Rep. 2015 Nov 2;5:15857. doi: 10.1038/srep15857.

12.

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.

Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, Li HJ, Zhao W.

Oncol Rep. 2011 Nov;26(5):1251-7. doi: 10.3892/or.2011.1378. Epub 2011 Jul 4.

PMID:
21743967
13.

Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.

Moreno-Vinasco L, Quijada H, Sammani S, Siegler J, Letsiou E, Deaton R, Saadat L, Zaidi RS, Messana J, Gann PH, Machado RF, Ma W, Camp SM, Wang T, Garcia JG.

Am J Respir Cell Mol Biol. 2014 Aug;51(2):223-8. doi: 10.1165/rcmb.2012-0519OC.

14.

Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury.

Zhao Y, Liu XZ, Tian WW, Guan YF, Wang P, Miao CY.

CNS Neurosci Ther. 2014 Jun;20(6):539-47. doi: 10.1111/cns.12273. Epub 2014 Apr 21.

PMID:
24750959
15.

Distinct effects of Nampt inhibition on mild and severe models of lipopolysaccharide-induced myocardial impairment.

Liu L, Wang P, Liang C, He D, Yu Y, Liu X.

Int Immunopharmacol. 2013 Oct;17(2):342-9. doi: 10.1016/j.intimp.2013.06.017. Epub 2013 Jul 2.

PMID:
23831038
16.

A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.

Song TY, Yeh SL, Hu ML, Chen MY, Yang NC.

Biogerontology. 2015 Dec;16(6):789-800. doi: 10.1007/s10522-015-9605-9. Epub 2015 Sep 2.

PMID:
26330291
17.

Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPARĪ³-Dependent Monocyte Differentiation and Function.

Bermudez B, Dahl TB, Medina I, Groeneweg M, Holm S, Montserrat-de la Paz S, Rousch M, Otten J, Herias V, Varela LM, Ranheim T, Yndestad A, Ortega-Gomez A, Abia R, Nagy L, Aukrust P, Muriana FJG, Halvorsen B, Biessen EAL.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1157-1167. doi: 10.1161/ATVBAHA.116.308187. Epub 2017 Apr 13.

PMID:
28408371
18.

Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes.

Schilling E, Wehrhahn J, Klein C, Raulien N, Ceglarek U, Hauschildt S.

Innate Immun. 2012 Jun;18(3):518-30. doi: 10.1177/1753425911423853. Epub 2011 Oct 5.

PMID:
21975728
19.

[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].

Wang F, Zhang WP.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011 Nov;40(6):680-4. Review. Chinese.

PMID:
22190532
20.

Supplemental Content

Support Center